SkinBioTherapeutics plc (LSE:SBTX) has announced the successful completion of a £4.2 million capital raise through a combined Placing, Subscription, and WRAP Retail Offer. A total of 24,704,836 new Ordinary Shares were issued at a price of 17 pence per share. The new shares are expected to begin trading on AIM by 24 June 2025, increasing the company’s total issued share capital and voting rights.
The funds raised will be used to advance SkinBioTherapeutics’ operational and strategic goals as it continues to develop and commercialize its innovative skin health solutions. While current financial metrics and technical indicators reflect challenges, this positive corporate development signals renewed investor confidence and potential for future growth.
About SkinBioTherapeutics plc
SkinBioTherapeutics plc is a biotechnology company focused on improving skin health through science-driven innovation. Operating at the intersection of consumer wellness and healthcare, the company develops microbiome-based products that address a range of skin conditions, serving both retail and medical markets.
Leave a Reply